Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease.

Donald M Kuhn, Catherine E Sykes, Timothy J Geddes, Karen L Eskow Jaunarajs, Christopher Bishop
Author Information
  1. Donald M Kuhn: Department of Psychiatry & Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA. donald.kuhn@wayne.edu

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine neurons of the nigrostriatal system, resulting in severe motor disturbances. Although much less appreciated, non-motor symptoms are also very common in PD and many can be traced to serotonin neuronal deficits. Tryptophan hydroxylase (TPH) 2, the rate-limiting enzyme in the serotonin biosynthesis, is a phenotypic marker for serotonin neurons and is known to be extremely labile to oxidation. Therefore, the oxidative processes that prevail in PD could cause TPH2 misfolding and modify serotonin neuronal function much as is seen in dopamine neurons. Oxidation of TPH2 inhibits enzyme activity and leads to the formation of high molecular weight aggregates in a dithiothreitol-reversible manner. Cysteine-scanning mutagenesis shows that as long as a single cysteine residue (out of a total of 13 per monomer) remains in TPH2, it cross-links upon oxidation and only cysteine-less mutants are resistant to this effect. The effects of oxidants on TPH2 catalytic function and cross-linking are also observed in intact TPH2-expressing HEK293 cells. Oxidation shifts TPH2 from the soluble compartment into membrane fractions and large inclusion bodies. Sequential non-reducing/reducing 2-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting confirmed that TPH2 was one of a small number of cytosolic proteins that form disulfide-bonded aggregates. The propensity of TPH2 to misfold upon oxidation of its cysteine residues is responsible for its catalytic lability and may be related to loss of serotonin neuronal function in PD and the emergence of non-motor (psychiatric) symptoms.

References

  1. Biochim Biophys Acta. 1997 Oct 17;1342(2):132-40 [PMID: 9392522]
  2. J Neurochem. 2009 Dec;111(5):1075-93 [PMID: 19780902]
  3. J Neurol Sci. 2006 Oct 25;248(1-2):151-7 [PMID: 16797028]
  4. Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):78-84 [PMID: 10581400]
  5. Neuroreport. 2003 Jan 20;14(1):73-6 [PMID: 12544834]
  6. J Neurochem. 2007 Oct;103(1):303-11 [PMID: 17587308]
  7. Depress Anxiety. 2000;12 Suppl 1:2-19 [PMID: 11098410]
  8. J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):222-8 [PMID: 11449029]
  9. J Histochem Cytochem. 1976 Jul;24(7):792-306 [PMID: 8567]
  10. J Neurochem. 2007 Nov;103(4):1567-73 [PMID: 17727633]
  11. J Biol Chem. 2006 Sep 22;281(38):28105-12 [PMID: 16864580]
  12. J Neurochem. 1996 Sep;67(3):1072-7 [PMID: 8752114]
  13. Brain Res. 1990 Feb 26;510(1):104-7 [PMID: 1691042]
  14. Neurology. 2002 May 28;58(10):1501-4 [PMID: 12034786]
  15. Brain. 2007 Jul;130(Pt 7):1819-33 [PMID: 17452372]
  16. J Neural Transm Gen Sect. 1992;90(3):183-97 [PMID: 1363050]
  17. Am J Psychiatry. 1989 May;146(5):577-87 [PMID: 2653053]
  18. J Neurosci. 2009 Jun 24;29(25):8103-13 [PMID: 19553450]
  19. Neurosci Biobehav Rev. 2011 Jan;35(3):556-64 [PMID: 20615430]
  20. Brain Res. 1990 Dec 24;537(1-2):83-7 [PMID: 1707735]
  21. Cell Tissue Res. 2004 Oct;318(1):121-34 [PMID: 15338272]
  22. J Neurochem. 1996 Feb;66(2):817-23 [PMID: 8592157]
  23. Cell. 2010 Mar 19;140(6):918-34 [PMID: 20303880]
  24. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3575-9 [PMID: 1059145]
  25. J Biol Chem. 2004 Oct 1;279(40):41352-60 [PMID: 15292244]
  26. Methods Enzymol. 1993;217:270-9 [PMID: 8474334]
  27. Anal Biochem. 1976 May 7;72:248-54 [PMID: 942051]
  28. Cell Mol Neurobiol. 2007 Dec;27(8):985-96 [PMID: 17934805]
  29. J Neuropathol Exp Neurol. 1991 Nov;50(6):743-55 [PMID: 1748881]
  30. J Biol Chem. 2007 Sep 21;282(38):28087-95 [PMID: 17666395]
  31. Brain Res. 2006 Apr 26;1085(1):11-8 [PMID: 16581041]
  32. J Biol Chem. 1980 May 10;255(9):4137-43 [PMID: 7372670]
  33. J Neurosci. 1997 Oct 1;17(19):7245-51 [PMID: 9295371]
  34. Trends Neurosci. 2001 Nov;24(11 Suppl):S7-14 [PMID: 11881748]
  35. Acta Psychiatr Scand. 2001 Nov;104(5):380-6 [PMID: 11722320]
  36. J Neural Transm Suppl. 1999;56:1-29 [PMID: 10370901]
  37. J Chem Neuroanat. 1992 Jul-Aug;5(4):327-30 [PMID: 1524719]
  38. J Neurol. 1987 Feb;234(2):94-6 [PMID: 2435855]
  39. Neurology. 2007 Oct 23;69(17):1701-11 [PMID: 17954785]
  40. Nat Struct Biol. 1999 May;6(5):401-2 [PMID: 10331859]
  41. Antioxid Redox Signal. 2009 Sep;11(9):2119-34 [PMID: 19243238]
  42. Physiol Rev. 2002 Apr;82(2):373-428 [PMID: 11917093]
  43. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1922-6 [PMID: 2155426]
  44. Ann Neurol. 2008 Dec;64 Suppl 2:S65-80 [PMID: 19127582]
  45. Antioxid Redox Signal. 2009 Sep;11(9):2135-49 [PMID: 19422283]
  46. Parkinsonism Relat Disord. 2008;14 Suppl 2:S154-8 [PMID: 18579429]
  47. J Biol Chem. 2002 Dec 13;277(50):48976-83 [PMID: 12351642]
  48. Nat Med. 2010 Jun;16(6):653-61 [PMID: 20495568]
  49. J Neurosci. 2010 Feb 10;30(6):2356-64 [PMID: 20147561]
  50. Ann Neurol. 1990 Apr;27(4):373-85 [PMID: 1972319]
  51. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30 [PMID: 19608786]
  52. Parkinsonism Relat Disord. 2008;14(1):37-42 [PMID: 17627863]
  53. J Neurochem. 1995 Aug;65(2):882-8 [PMID: 7616249]
  54. J Neurosci. 1998 Sep 15;18(18):7111-7 [PMID: 9736634]
  55. Sci STKE. 2004 Jun 22;2004(239):pe27 [PMID: 15226511]
  56. Lancet Neurol. 2006 Mar;5(3):235-45 [PMID: 16488379]
  57. Cell. 1997 Aug 8;90(3):549-58 [PMID: 9267034]
  58. J Biol Chem. 2008 May 16;283(20):13771-9 [PMID: 18362144]
  59. Clin Neurol Neurosurg. 2009 Jul;111(6):523-6 [PMID: 19297081]
  60. EMBO J. 2008 Jan 23;27(2):336-49 [PMID: 18216876]
  61. J Biol Chem. 2004 May 21;279(21):21749-58 [PMID: 15031298]
  62. FASEB J. 2005 Dec;19(14):2060-2 [PMID: 16186172]
  63. Brain Res. 1983 Sep 26;275(2):321-8 [PMID: 6626985]
  64. J Neurochem. 2007 Sep;102(6):1887-1894 [PMID: 17539919]
  65. J Biol Chem. 1999 Oct 15;274(42):29726-32 [PMID: 10514446]
  66. Neurobiol Dis. 2009 May;34(2):279-90 [PMID: 19385059]
  67. J Biol Chem. 2008 Jan 11;283(2):866-74 [PMID: 18006498]
  68. Brain. 2008 Jan;131(Pt 1):120-31 [PMID: 17956909]
  69. Nature. 2003 Dec 18;426(6968):895-9 [PMID: 14685250]
  70. Br J Psychiatry. 1999 Apr;174:307-11 [PMID: 10533549]
  71. J Neural Transm. 1985;62(1-2):107-15 [PMID: 4020380]
  72. J Neurochem. 2006 Feb;96(3):758-65 [PMID: 16405505]
  73. Am J Psychiatry. 2002 Nov;159(11):1862-8 [PMID: 12411220]
  74. Annu Rev Neurosci. 2008;31:151-73 [PMID: 18558852]
  75. Neurobiol Dis. 2010 Apr;38(1):136-43 [PMID: 20096781]
  76. J Biol Chem. 2002 Apr 19;277(16):14336-42 [PMID: 11834745]
  77. Neurology. 1984 May;34(5):642-6 [PMID: 6200801]
  78. Methods Enzymol. 1995;251:123-33 [PMID: 7651192]
  79. Trends Pharmacol Sci. 2009 Sep;30(9):475-83 [PMID: 19729209]

Grants

  1. I01 RX000458/RRD VA
  2. DA017327/NIDA NIH HHS
  3. R01 DA017327/NIDA NIH HHS
  4. R01 DA010756-13/NIDA NIH HHS
  5. DA010756/NIDA NIH HHS
  6. R01 DA010756/NIDA NIH HHS
  7. R01 DA017327-05/NIDA NIH HHS

MeSH Term

Brain
Catalytic Domain
Cross-Linking Reagents
Cysteine
Dementia
Disulfides
HEK293 Cells
Humans
Neurons
Oxidation-Reduction
Oxidative Stress
Parkinson Disease
Protein Binding
Protein Folding
Serotonin
Tryptophan Hydroxylase

Chemicals

Cross-Linking Reagents
Disulfides
Serotonin
TPH2 protein, human
Tryptophan Hydroxylase
Cysteine

Word Cloud

Created with Highcharts 10.0.0TPH2serotoninPDneuronsnon-motorsymptomsneuronaloxidationfunctionaggregatesuponParkinson'sdiseaselossdopaminemuchalsodeficitsTryptophanhydroxylase2enzymeOxidationcysteinecatalyticcross-linkingprogressiveneurodegenerativedisordercharacterizednigrostriatalsystemresultingseveremotordisturbancesAlthoughlessappreciatedcommonmanycantracedTPHrate-limitingbiosynthesisphenotypicmarkerknownextremelylabileThereforeoxidativeprocessesprevailcausemisfoldingmodifyseeninhibitsactivityleadsformationhighmolecularweightdithiothreitol-reversiblemannerCysteine-scanningmutagenesisshowslongsingleresiduetotal13permonomerremainscross-linkscysteine-lessmutantsresistanteffecteffectsoxidantsobservedintactTPH2-expressingHEK293cellsshiftssolublecompartmentmembranefractionslargeinclusionbodiesSequentialnon-reducing/reducing2-dimensionalsodiumdodecylsulfate-polyacrylamidegelelectrophoresisimmunoblottingconfirmedonesmallnumbercytosolicproteinsformdisulfide-bondedpropensitymisfoldresiduesresponsiblelabilitymayrelatedemergencepsychiatricdisulfideoxidation:possiblelink

Similar Articles

Cited By